News

Taiho acquires Cullinan Pearl and rights to CLN 081/TAS 6417.

Read time: 1 mins

Published:15th May 2022

Cullinan Oncology, and Taiho Pharmaceutical Co., Ltd. announced an agreement through which Taiho will acquire Cullinan Pearl Corp.

(Cullinan Pearl) and co-develop and co-commercialize Cullinan Oncology’s lead program, CLN-081/TAS6417 (development code in Cullinan Oncology: CLN-081, development code in Taiho: TAS6417), an orally available, differentiated, irreversible EGFR inhibitor that selectively targets cells expressing EGFR exon 20 insertion mutations while sparing cells expressing wild-type EGFR.

Type: industry

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Industry news

Eyenovia Inc.,to accelerate development of MicroPine and explore alternatives to maximize shareholder value.

Eyenovia, Inc. announced its plans for accelerating development of its potential multi-billion dollar product for pediatric progressive myopia (MicroPine) and initiated a process to explore strategic alternatives to maximize shareholder value

1 mins

Industry news

GenMab A/S to acquire ProfoundBio and with it Rina-S, an FRalpha ADC, to treat ovarian cancer

Genmab A/S and ProfoundBio, Inc. announce that the companies have entered into a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction.

1 min

Industry news

Acorda Therapeutics files for voluntary bankruptcy

Acorda Therapeutics, Inc. announced that it has entered into an asset purchase agreement with Merz Therapeutics to purchase substantially all of the assets of Acorda, including the rights to Inbrija, Ampyra, and Fampyra for $185 million.

1 min

See all news